Zou, Yilong
Palte, Michael J.
Deik, Amy A.
Li, Haoxin
Eaton, John K. http://orcid.org/0000-0003-4633-5546
Wang, Wenyu
Tseng, Yuen-Yi
Deasy, Rebecca http://orcid.org/0000-0001-9143-6296
Kost-Alimova, Maria
Dančík, Vlado
Leshchiner, Elizaveta S.
Viswanathan, Vasanthi S.
Signoretti, Sabina
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Boehm, Jesse S. http://orcid.org/0000-0002-6795-6336
Wagner, Bridget K.
Doench, John G. http://orcid.org/0000-0002-3707-9889
Clish, Clary B. http://orcid.org/0000-0001-8259-9245
Clemons, Paul A. http://orcid.org/0000-0002-1800-5112
Schreiber, Stuart L. http://orcid.org/0000-0003-1922-7558
Article History
Received: 20 December 2018
Accepted: 4 March 2019
First Online: 8 April 2019
Competing interests
: S.L.S. is a member of the Board of Directors of the Genomics Institute of the Novartis Research Foundation (GNF); a shareholder and member of the Board of Directors of Jnana Therapeutics; a shareholder of Forma Therapeutics; a shareholder of and adviser to Decibel Therapeutics and Eikonizo Therapeutics; an adviser to Eisai, Inc., the Ono Pharma Foundation, and F-Prime Capital Partners; and a Novartis Faculty Scholar. P.A.C. is an adviser to Pfizer, Inc. S. Signoretti has consulting or advisory role for AstraZeneca/MedImmune, Merck, AACR, NCI; royalties from Biogenex Laboratories; and research funding from AstraZeneca, Exelixis, Bristol-Myers Squibb. T.K.C. receives institutional and personal research funds from AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Takeda; and receives personal honoraria from AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics; and has consulting or advisory role for AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group. No speaker’s bureau. No leadership or employment in for-profit companies. Other present or past leadership roles for T.K.C.: Director of GU Oncology Division at Dana-Farber and past President of medical Staff at Dana-Farber), member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney cancer Association Medical and Scientific Steering Committee). No Patents, royalties or other intellectual properties. Travel, accommodations, expenses, in relation to consulting, advisory roles, or honoraria. Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. CV provided upon request for scope of clinical practice and research. The remaining authors declare no competing interests.